Objectives: The aim of this study was to compare the pharmacokinetic characteristics of two 10-mg baclofen formulations and to assess
We describe a patient with end-stage kidney disease receiving hemodialysis who developed neurotoxicity and hemodynamic instability after receiving baclofen for
Intrathecal baclofen (ITB) has proven to be an effective and safe treatment for severe spasticity
A pharmacokinetic-pharmacodynamic model was then built by implementing an existing mathematical model of BP in rats
After a baclofen loading dose on day 1, daily doses were divided into 3 intakes adapted to glomerular filtration rate (GFR) and blood samples were withdrawn on day 3 for
14 CLINICAL STUDIES Oral Granules: 5 mg, 10 mg, or 20 mg baclofen as white to off-white, strawberry flavored granules in a single dose packet
Baclofen, 4-amino-3-[p-chlorophenyl]butyric acid, acts as an agonist of GABA B receptors, which reduces calcium influx into presynaptic nerve terminals
Tizanidine is an FDA-approved drug for managing spasticity
Abrupt withdrawal (injection): Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, which in rare cases has advanced to rhabdomyolysis, multiple organ-system failure, and death
Baclofen pharmacokinetics were investigated by a non-compartment analysis and a population approach in 20 patients under mechanical ventilation
i
for A liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed at the Clinical Pharmacokinetics Research Laboratory of the University of Rhode Island to quantify baclofen in the Seventy-four percent oral bioavailability indicates that smaller doses of intravenous baclofen are needed to attain comparable total drug exposures, and adverse effects were mild in severity and not related to either dose or route of administration
The aim of this study was the development of a pharmacokinetic-pharmacodynamic (PK/PD) model of the antinociceptive effect of baclofen in mice
Müller, J
5 mg 3 times a day to a maximum Background: Pharmacogenomic variability can contribute to differences in pharmacokinetics and clinical responses
This is associated with the weakly pronounced lipophilicity of the agent in question and with the protective properties of the blood-brain barrier